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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of intraoperative neuromonitoring (IONM) versus visual nerve identification for prevention of recurrent laryngeal
nerve injury in adults undergoing thyroid surgery.
B A C K G R O U N D
Description of the condition
The visual identification of the recurrent inferior laryngeal nerve
(RILN) is considered the safest method to prevent nerve injury
during thyroid and parathyroid surgery (Deniwar 2015a). Gen-
erally, the rate of nerve injury is higher in cases of thyroid carci-
noma, Flajani-Graves-Basedowdisease, goitre, thyroid reoperation
surgery, failure of nerve identification and surgeon’s low experi-
ence (Calò 2014a). Intraoperative neuromonitoring (IONM) has
been introduced in order to facilitate the localisation of the RILN
and prevent its injury during surgery (Duclos 2011). A study that
included 686 participants demonstrated that use of IONM de-
creased the incidence of RILN palsy (from 7.6% to 4.7%) (Duclos
2011). IONM was reported to reduce the prevalence of transient
RILN injury (Barczy ski 2009), and to increase surgeon’s accu-
racy during nerve preparation, particularly during video-assisted
thyroid surgery (Dionigi 2009). When used by experienced thy-
roid surgeons (RILN injury rate of less than 1%), the IONM did
not show a significant improvement in the postsurgery outcomes
(Barczy ski 2009). However, in procedures that low-volume sur-
geons performed, the use of IONM was associated with a signifi-
cant reduction in postsurgical permanent recurrent laryngeal nerve
palsy (Dralle 2004). Low-volume surgeons was defined as sur-
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geons that perform fewer than 25 thyroidectomies per year (Adam
2016). With low-volume surgeons, RILN monitoring helped to
reduce the permanent RILN palsy rate (0.9%) (Sosa 1998). With
low-volume surgeons, the permanent RILN palsy rates were high-
est after visual nerve identification (1.4%) (Sosa 1998). RILN
monitoring might be a useful technique that guides the cautious
handling of the recurrent nerve by low-volume surgeons. High-
volume surgeons may benefit from RILN monitoring in difficult
situations (Dralle 2004). Zheng 2013 published a meta-analysis
of 14 different studies, which included 36,487 participants, and
concluded that IONM decreases the risk of transient RILN palsy
without affecting the rates of permanent injuries.
Description of the intervention
The RILN is normally identified by palpation and surgical dissec-
tion. The IONM was introduced in the attempt to identify the
nerve by using an electrode (Dequanter 2015). In order tomeasure
the nerve response, the electric field is converted to an acoustic
signal, the potentials of which are recorded. In procedures per-
formed by low-volume surgeons, the use of IONMwas associated
with a significant reduction in postsurgical permanent recurrent
laryngeal nerve palsy.
The IONMsystemoperateswith two surface electrodes positioned
upon an endotracheal tube, which is 7mm in diameter. During in-
tubation, the anaesthetist inserts, under direct vision, the endotra-
cheal tube between the vocal folds (Figure 1). The RILN is stimu-
lated by a monopolar electrode, using the interrupted stimulation
technique (1 mA, 100 ms impulse duration and 4 Hz frequency).
In the case of a bifurcated RILN, the poststimulation response for
each nerve branch is included. The endotracheal tube electromyo-
graphy is used to detect the adduction of the vocal folds (Figure 2).
A posterior cricoarytenoid muscle contraction, revealed by direct
fingers palpation, is used to detect the abduction of the vocal folds
(Figure 3).
Figure 1. Nerve integrity monitoring endotracheal tube for electromyography signals of a patient’s
laryngeal muscles
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Figure 2. Monitoring endotracheal tube in position positioned at the patient’s vocal folds
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Figure 3. Basic monitoring equipment setup: ET = endotracheal tube; REC = recording electrodes; GND =
ground electrodes; EMG = electromyography
During the intervention, the thyroid lobe is shifted medially and
the upper thyroid vessels are tied and cut. The RILN is then iden-
tified, dissected and stimulated. At the beginning of thyroidec-
tomy, to make sure that the neuromonitoring system is working,
the vagus nerve is stimulated. Proceeding with the operation, the
inferior laryngeal nerve is repeatedly stimulated. At the end of the
operation, both the vagus and the recurrent nerve are stimulated
in the attempt to predict the postoperative outcome (Calò 2014b).
In IONM, the first stimulating electrode is used to contact with
the RILN, followed with the conduction of the electrical stimu-
lation of the RILN. The second recording electrode receives the
electrical signal and a monitor records the signal with a sound.
If the RILN is nearby, the surgeon sees the waveform on the dis-
player at the same time (Zheng 2015). Both the stimulating and
recording electrodes are positioned on the sternumor the shoulder,
while the interface connector device is linked to the monitoring
system. Sonor systems with alarms indicate signal abnormalities,
while optic waveformmonitors show amplitude, threshold and la-
tency records, which can discriminate true from false signals, giv-
ing a real time feedback by monitoring electromyography (EMG)
responses.
IONM can also be performed in a continuous way, for instance
when the stimulating and recording systems are connected to an in-
terface connector device, which is linked to grounding electrodes.
Continuous IONM can disclose earlier changes in nerve function,
which may be a warning of impending nerve injury (Deniwar
2015a). Continuous IONM seems to be superior to intermitted
intraoperative neural monitoring because it enhances standardisa-
tion by permanent vagus nerve stimulation, and it provides entire
and constant RILN function monitoring as the surgeon dissects
and removes the thyroid gland.
Following stimulation of the ipsilateral vagus nerve, the absence
of an EMG signal is defined as a loss of signal. An intraoperative
algorithm is employed to differentiate between true and false loss
of signal. In cases of true loss of signal, the neuromapping tech-
nique is used to determine the type of nerve damage and localise
the injury site. Following thyroid lobectomy, the loss of signal af-
ter vagal stimulation is considered a positive test result. When the
laryngoscopy confirms an ipsilateral vocal cord paresis, it is con-
sidered a true positive result. Conversely, a normal mobility of the
ipsilateral vocal fold is considered a false positive result. Following
thyroid lobectomy, the detection of a normal signal after vagal
stimulation is considered a negative test result. When the postop-
erative laryngoscopy confirms a normal mobility of the ipsilateral
vocal fold, it is considered a true negative result. Conversely, the
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detection of an ipsilateral vocal fold paresis is considered as a false
negative result of the EMG signal.
Co-operation between the surgeon and the anaesthesiologist is es-
sential for successful neuromonitoring. The use of neuromuscu-
lar blocking agents should be carefully considered and avoided if
possible, as they reduce response amplitudes from the vagus, the
RILN and the external branch of the superior laryngeal nerve,
which may hinder injury detection.
Adverse effects of the intervention
Chen and colleagues analysed the adverse effects of the procedure
of neuromonitoring in a cohort of 3029 patients undergoing thy-
roid surgery: preoperative complications (bucking, deep tracheal
catheter placement, tracheal catheter rotation, over-secretion and
unstable signal, unstable blood flow dynamics and oral mucosa in-
jury) and reported postoperative complications (throat pain, pha-
ryngeal discomfort, hoarse voice and joint half-dislocation, inhala-
tion pneumonia, dry eye syndrome, ear and neck numbness and
conjunctival congestion) (Chen 2015).
How the intervention might work
During surgery for thyroid carcinoma with lymph nodes dissec-
tion, thyroid reoperation surgery, or in the presence of anatomic
variability, IONM can help surgeons to identify the RILN
(Dequanter 2015), and may offer a real benefit for lowering nerve
injury rates (Malik 2016). Regarding the vocal cord functionality,
an intact monitoring signal at the end of the surgery is associ-
ated with a positive outcome. In fact, the negative predictive value
of the procedure is very high (97% to 99%) (Calò 2014b). This
means that if 100 patients have an intact monitoring signal at the
end of the surgery, 97 to 99 patients out of these 100 patients will
have normal vocal cord functionality. On the other hand, with a
loss of signal at the end of operation, the positive predictive value
of the procedure is low (33% to 37%), and the occurrence of vo-
cal cord palsy is unpredictable (Calò 2014b). This means that if
100 patients have a loss of signal at the end of operation, just 33
to 37 out of these 100 patients will have vocal cord palsy. Dur-
ing thyroid surgery, neuromonitoring facilitates the identification
of RILN, verifying the functional integrity of the nerve (Chiang
2011; Dequanter 2015). In fact, a positive IONM can demon-
strate intact nerve function intraoperatively (Chiang 2010). Be-
cause most of the injured nerves appear intact, IONM can prop-
erly prognosticate postoperative nerve function, which is difficult
to detect by visual identification (Dralle 2004). Neuromonitoring
can also detect anatomical variation and abnormal courses of the
nerves, which are at high risk of injury if not detected (Deniwar
2015b).
Why it is important to do this review
Recent guidelines from the American Academy of Otolaryngol-
ogy - Head and Neck Surgery recommend IONM use in thyroid
surgery to prevent nerve damage (Chandrasekhar 2013). IONM
is currently used in 80% of thyroidectomies performed by neck
surgeons and bymore than 50% of general surgeons in theUSA. It
is more commonly used by higher-volume surgeons (Al-Qurayshi
2016). More clinical trials are needed to further clarify the effects
of IONM. In themeta-analysis byHiggins 2011a and in the recent
meta-analysis by Pisanu 2014, IONM and visual nerve identifi-
cation did not demonstrate a statistically significant difference in
rates of transient, total or persistent vocal fold palsy. Pisanu 2014
analysed 20 trials that included 23,152 participants and showed
that overall RILN palsy rates for IONM versus visualisation alone
were 3.5%versus 3.7%.The role of IONMduring thyroid surgery
is still debatable, as no consensus exists regarding the prevention of
recurrent nerve injury (Deniwar 2015a). There are three primary
reasons that this review will improve upon the previous reviews by
Higgins 2011a and Pisanu 2014. First, both Higgins 2011a and
Pisanu 2014 highlighted the need for more studies on this topic
that have fewer methodological flaws; both reviews called for more
and better controlled randomised controlled trials (RCTs). Pisanu
2014 specifically called for further studies that include high-qual-
ity multicentre, prospective, randomised trials based on strict cri-
teria of standardisation and subsequent meta-analysis to verify the
outcomes of interest. If those calls have been heeded, we would
expect this Cochrane review to include more trials with better
methodological quality. Second, we will include trials published
since the last search in August 2013 by Pisanu 2014. Finally, we
propose to investigate additional patient-important outcomes that
have not yet been investigated in previous reviews, such as health-
related quality of life, all-cause mortality and socioeconomic ef-
fects.
O B J E C T I V E S
To assess the effects of intraoperative neuromonitoring (IONM)
versus visual nerve identification for prevention of recurrent la-
ryngeal nerve injury in adults undergoing thyroid surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs).
Types of participants
Adults (older than 18 years) undergoing thyroidectomy.
A thyroidectomy is an operation that involves the surgical removal
of all or part of the thyroid gland. We will evaluate two techniques
in this review: partial and total thyroidectomy. We define partial
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thyroidectomy as the surgical removal of a portion of the thyroid
gland and total thyroidectomy as the surgical removal of the entire
gland.
Types of interventions
We plan to investigate the following comparison of intervention
versus control/comparator.
Intervention
• Intraoperative neuromonitoring (IONM) with and without
visual nerve identification during thyroidectomy.
Comparator
• Visual nerve identification only during thyroidectomy.
Concomitant interventions will have to be the same in both the
intervention and comparator groups to establish fair comparisons.
Minimum duration of follow-up
Minimal duration of follow-up will be six months.
We will define extended follow-up periods (also called open-label
extension studies) as follow-up of participants once the original
trial, as specified in the trial protocol. has been terminated. How-
ever, such studies are frequently of an observational nature and
we will only evaluate them for adverse events (Buch 2011; Megan
2012).
Specific exclusion criteria
• Clinical trials that evaluate people with a previous history of
neck surgery and laryngeal nerve injury.
Types of outcome measures
We will not exclude a trial only on the basis that one or several
of our primary or secondary outcome measures were not reported
in the publication. In case none of our primary or secondary out-
comes was reported in the trial we will not include this trial but
will provide some basic information in an additional table.
Primary outcomes
• Permanent recurrent inferior laryngeal nerve (RILN) palsy.
• Transient RILN palsy.
• Health-related quality of life.
Secondary outcomes
• Adverse events other than permanent or transient RILN
palsy.
• Operative time.
• All-cause mortality.
• Socioeconomic effects.
Method and timing of outcome measurement
• Permanent RILN palsy: defined as an injury detected
clinically, by laryngoscopy or both in which the motility of the
vocal cords does not recover within six months after surgery.
• Transient RILN palsy: defined as an injury detected
clinically, by laryngoscopy or both in which the motility of the
vocal cords recovered within six months after surgery.
• Health-related quality of life: evaluated by a validated
instrument such as the Short Form 36 (SF-36) or Quality of Life-
Thyroid Version (QOL-TV) measured at 30 days and thereafter.
• Adverse events other than permanent or transient RILN
palsy: such as pain and measured at any time after participants
were randomised to intervention/comparator groups.
• Operative time: defined as the time from the first skin
incision to skin closure; measured at the end of the operation.
• All-cause mortality: defined as death from any cause during
the first 30 days after the operation (early mortality) and later
(late mortality).
• Socioeconomic effects: direct costs, including those related
to surgical supplies and to hospital stay; measured at 30 days
from the operation.
’Summary of findings’ table
We will present a ’Summary of finding’ table to report the follow-
ing outcomes, listed according to priority.
1. Permanent RILN palsy.
2. Transient RILN palsy.
3. Health-related quality of life.
4. Adverse events other than permanent or transient RILN
palsy.
5. Operative time.
6. All-cause mortality.
7. Socioeconomic effects.
Search methods for identification of studies
Electronic searches
We will search the following sources from inception of each
database to the specified date and will place no restrictions on the
language of publication.
• Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO).
• MEDLINE Ovid (Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R); from 1946 onwards).
• Embase Ovid (from 1974 onwards).
• ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform (ICTRP) (www.who.int/trialsearch/).
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We will continuously apply a MEDLINE (via Ovid SP) email
alert service established by theCochraneMetabolic and Endocrine
Disorders (CMED)Group, to identify newly published trials using
the same search strategy as described for MEDLINE (for details
on search strategies, see Appendix 1). After supplying the final
review draft for editorial approval, the CMEDGroup will perform
a complete updated search on all databases available at the editorial
office and send the results to the review authors. Shouldwe identify
new trials for inclusion, we will evaluate these, incorporate the
findings into our review and resubmit another review draft (Beller
2013).
If we detect additional relevant key words during any electronic
or other searches, we will modify the electronic search strategies
to incorporate these terms and will document the changes to the
search strategy.
Searching other resources
We will try to identify other potentially eligible trials or ancillary
publications by searching the reference lists of included trials, sys-
tematic reviews, meta-analyses and health technology assessment
reports. In addition we will contact the authors of included trials
to identify any additional information on the retrieved trials and
to determine if further trials exist, which we may have missed.
We will not use abstracts or conference proceedings for data ex-
traction because this information source does not fulfil the Con-
solidated Standards of Reporting Trials (CONSORT) require-
ments which is “an evidence-based, minimum set of recommenda-
tions for reporting randomized trials” (CONSORT 2016; Scherer
2007).
Data collection and analysis
Selection of studies
Two review authors (RC, VD) will independently screen the ab-
stract or title, or both, of every record retrieved, to determinewhich
trials we should assess further.We will investigate the full- text arti-
cles of all potentially relevant articles.We will resolve discrepancies
through consensus or by recourse to a third review author (AA). If
we cannot resolve a disagreement, we will categorise the trial as a
’study awaiting classification’ and will contact the trial authors for
clarification. Wewill present an adapted PRISMA flow diagram to
show the process of trial selection (Liberati 2009). We will list all
articles excluded after full-text assessment in a ’Characteristics of
excluded studies’ table and will provide the reasons for exclusion.
Data extraction and management
For trials that fulfil inclusion criteria, two review authors (RC,
VD) will independently extract key participant and intervention
characteristics. We will report data on efficacy outcomes and ad-
verse events using standard data extraction sheets from theCMED
Group. We will resolve any disagreements by discussion or, if re-
quired, we will consult a third review author (AA).
We will provide information about potentially relevant ongoing
trials, including trial identifiers, in the ’Characteristics of ongo-
ing trials’ table and in a joint appendix ’Matrix of trial endpoint
(publications and trial documents)’. We will try to find the proto-
col for each included trial and will report primary, secondary and
other outcomes in comparison with data in publications in a joint
appendix.
We will email all authors of included trials to enquire whether
they would be willing to answer questions regarding their trials.
We will present the results of this survey in an appendix. We will
thereafter seek relevant missing information on the trial from the
primary trial author(s), if required.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary trial, we will maximise the informa-
tion yield by collating all available data and we will use the most
complete dataset aggregated across all known publications. We
will list duplicate publications, companion documents, multiple
reports of a primary trial and trial documents of included trials
(such as trial registry information) as secondary references under
the study identifier (ID) of the included trial. Furthermore, wewill
also list duplicate publications, companion documents, multiple
reports of a trial and trial documents of excluded trials (such as
trial registry information) as secondary references under the study
ID of the excluded trial.
Data from clinical trial registers
If data from included trials are available as study results in clinical
trial registers such as ClinicalTrials.gov or similar sources, we will
make full use of this information and extract the data. If there is also
a full publication of the trial, we will collate and critically appraise
all available data. If an included trial ismarked as a completed study
in a clinical trial register but no additional information (study
results, publication or both) is available, we will add this trial to
the ’Characteristics of studies awaiting classification’ table.
Assessment of risk of bias in included studies
Two review authors (RC, VD) will independently assess the risk
of bias of each included trial. We will resolve any disagreements by
consensus, or by consulting a third review author (AA). In cases of
disagreement, we will consult the rest of the review author team
and we will make a judgement based on consensus. If adequate
information is unavailable from the trials, trial protocols or both,
we will contact the trial authors to recover missing data on ’Risk
of bias’ items.
We will use the Cochrane ’Risk of bias’ assessment tool (Higgins
2011b;Higgins 2011c), and we will judge the ’Risk of bias’ criteria
as at either low, high or unclear risk. We will evaluate individual
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bias items as described in the Cochrane Handbook for Systematic
Reviews of Interventions according to the criteria and associated
categorisations contained therein (Higgins 2011c).
Random sequence generation (selection bias due to inadequate
generation of a randomised sequence) - assessment at trial level
For each included trial we will describe the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
• Low risk of bias: the trial authors achieved sequence
generation using computer-generated random numbers or a
random numbers table. Drawing of lots, tossing a coin, shuffling
cards or envelopes, and throwing dice are adequate if an
independent person performed this who was not otherwise
involved in the trial. We will consider the use of the
minimisation technique as equivalent to being random.
• Unclear risk of bias: insufficient information about the
sequence generation process.
• High risk of bias: the sequence generation method was non-
random or quasi-random (e.g. sequence generated by odd or
even date of birth; sequence generated by some rule based on
date (or day) of admission; sequence generated by some rule
based on hospital or clinic record number; allocation by
judgement of the clinician; allocation by preference of the
participant; allocation based on the results of a laboratory test or
a series of tests; or allocation by availability of the intervention).
Allocation concealment (selection bias due to inadequate con-
cealment of allocation prior to assignment) - assessment at
trial level
We will describe for each included trial the method used to con-
ceal allocation to interventions prior to assignment and we will
assess whether intervention allocation could have been foreseen in
advance of or during recruitment, or changed after assignment.
• Low risk of bias: central allocation (including telephone,
interactive voice-recorder, internet-based and pharmacy-
controlled randomisation); sequentially numbered drug
containers of identical appearance; sequentially numbered,
opaque, sealed envelopes.
• Unclear risk of bias: insufficient information about the
allocation concealment.
• High risk of bias: using an open random allocation schedule
(e.g. a list of random numbers); assignment envelopes were used
without appropriate safeguards; alternation or rotation; date of
birth; case record number; any other explicitly unconcealed
procedure.
We will also evaluate trial baseline data to incorporate assessment
of baseline imbalance into the ’Risk of bias’ judgement for se-
lection bias (Corbett 2014). Chance imbalances may also affect
judgements on the risk of attrition bias. In the case of unadjusted
analyses, we will distinguish between trials we rate as at low risk
of bias on the basis of both randomisation methods and baseline
similarity, and trials we judge as at low risk of bias on the basis of
baseline similarity alone (Corbett 2014).We will re-classify judge-
ments of unclear, low or high risk of selection bias as specified in
Appendix 2.
Blinding of participants and study personnel (performance
bias due to knowledge of the allocated interventions by partic-
ipants and personnel during the trial) - assessment at outcome
level
We will evaluate the risk of detection bias separately for each out-
come (Hróbjartsson 2013). We will note whether endpoints were
self-reported, investigator-assessed or adjudicated outcome mea-
sures (see below).
• Low risk of bias: blinding of participants and key study
personnel is ensured, and it is unlikely that the blinding could
have been broken; no blinding or incomplete blinding, but we
judge that the outcome is unlikely to have been influenced by
lack of blinding.
• Unclear risk of bias: insufficient information about the
blinding of participants and study personnel; the trial does not
address this outcome.
• High risk of bias: no blinding or incomplete blinding, and
the outcome is likely to have been influenced by lack of blinding;
blinding of trial participants and key personnel attempted, but
likely that the blinding could have been broken, and the
outcome is likely to be influenced by lack of blinding.
Blinding of outcome assessment (detection bias due to knowl-
edge of the allocated interventions by outcome assessment) -
assessment at outcome level
We will evaluate the risk of detection bias separately for each out-
come (Hróbjartsson 2013). We will note whether endpoints were
self-reported, investigator-assessed or adjudicated outcome mea-
sures (see below).
• Low risk of bias: blinding of outcome assessment is ensured,
and it is unlikely that the blinding could have been broken; no
blinding of outcome assessment, but we judge that the outcome
measurement is unlikely to have been influenced by lack of
blinding.
• Unclear risk of bias: insufficient information about the
blinding of outcome assessors; the trial did not address this
outcome.
• High risk of bias: no blinding of outcome assessment, and
the outcome measurement is likely to have been influenced by
lack of blinding; blinding of outcome assessment, but likely that
the blinding could have been broken, and the outcome
measurement is likely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias due to amount, na-
ture or handling of incomplete outcome data) - assessment at
outcome level
For each included trial and or each outcome, we will describe the
completeness of data, including attrition and exclusions from the
analyses. We will state whether the trial reported attrition and ex-
clusions, and the number of participants included in the analysis at
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each stage (compared with the number of randomised participants
per intervention/comparator groups). We will also note if the trial
reported the reasons for attrition or exclusion and whether miss-
ing data were balanced across groups or were related to outcomes.
We will consider the implications of missing outcome data per
outcome such as high dropout rates (e.g. above 15%) or disparate
attrition rates (e.g. difference of 10% or more between trial arms).
• Low risk of bias: no missing outcome data; reasons for
missing outcome data unlikely to be related to true outcome (for
survival data, censoring unlikely to introduce bias); missing
outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups; for
dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk is not enough to have a
clinically relevant impact on the intervention effect estimate; for
continuous outcome data, plausible effect size (mean difference
or standardised mean difference) among missing outcomes is not
enough to have a clinically relevant impact on observed effect
size; appropriate methods, such as multiple imputation, were
used to handle missing data.
• Unclear risk of bias: insufficient information to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias; the trial did not
address this outcome.
• High risk of bias: reason for missing outcome data is likely
to be related to true outcome, with either imbalance in numbers
or reasons for missing data across intervention groups; for
dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically
relevant bias in the intervention effect estimate; for continuous
outcome data, plausible effect size (mean difference or
standardised mean difference) among missing outcomes enough
to induce clinically-relevant bias in observed effect size; ’as-
treated’ or similar analysis done with substantial departure of the
intervention received from that assigned at randomisation;
potentially inappropriate application of simple imputation.
Selective reporting (reporting bias due to selective outcome
reporting) - assessment at trial level
We will assess outcome reporting bias by integrating the results
of the appendix ’Matrix of trial endpoints (publications and trial
documents)’ (Boutron 2014; Jones 2015; Mathieu 2009), with
those of the appendix ’High risk of outcome reporting bias ac-
cording to ORBIT classification’ (Kirkham 2010). This analysis
will form the basis for the judgement of selective reporting.
• Low risk of bias: the trial protocol is available and all of the
trial’s prespecified (primary and secondary) outcomes that are of
interest in the review have been reported in the prespecified way;
the study protocol is unavailable, but it is clear that the published
reports include all expected outcomes (ORBIT classification).
• Unclear risk of bias: insufficient information about selective
reporting.
• High risk of bias: not all of the trial’s pre-specified primary
outcomes are reported; one or more primary outcomes are
reported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not prespecified; one or more
reported primary outcomes were not prespecified (unless clear
justification for their reporting is provided, such as an
unexpected adverse effect); one or more outcomes of interest in
the Cochrane review are reported incompletely so that we cannot
enter them in a meta-analysis; the trial report fails to include
results for a key outcome that we would expect to have been
reported for such a trial (ORBIT classification).
Other bias (bias due to problems not covered elsewhere) - as-
sessment at trial level
• Low risk of bias: the trial appears to be free of other sources
of bias.
• Unclear risk of bias: there is insufficient information to
assess whether an important risk of bias existed; insufficient
rationale or evidence that an identified problem introduced bias.
• High risk of bias: the trial has a potential source of bias
related to the specific trial design used; the trial has been claimed
to have been fraudulent; or the trial had some other serious
problem.
We will present a ’Risk of bias’ graph and a ’Risk of bias’ summary
figure.
We will distinguish between self-reported, investigator-assessed
and adjudicated outcome measures.
We define the following outcomes as self-reported.
• Permanent RILN palsy, as reported by trial participants.
• Transient RILN palsy, as reported by trial participants.
• Health-related quality of life.
• Adverse events other than permanent or transient RILN
palsy, as reported by trial participants.
We define the following outcomes as investigator-assessed.
• Permanent RILN palsy, as measured by trial personnel.
• Transient RILN palsy, as measured by trial personnel.
• Adverse events other than permanent or transient RILN
palsy, as measured by trial personnel.
• All-cause mortality.
• Operative time.
• Socioeconomic effects.
Summary assessment of risk of bias
Risk of bias for a trial across outcomes: some ’Risk of bias’
domains, such as selectionbias (sequence generation and allocation
sequence concealment), affect the risk of bias across all outcome
measures in a trial. In case of high risk of selection bias, we will
mark all endpoints investigated in the associated trial as at high
risk. Otherwise, we will not perform a summary assessment of the
risk of bias across all outcomes for a trial.
Risk of bias for an outcome within a trial and across domains:
we will assess the risk of bias for an outcome measure by including
all entries relevant to that outcome (i.e. both trial-level entries and
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outcome-specific entries). We consider low risk of bias to denote
a low risk of bias for all key domains, unclear risk to denote an
unclear risk of bias for one or more key domains and high risk to
denote a high risk of bias for one or more key domains.
Risk of bias for an outcome across trials and across domains:
these are our main summary assessments that we will incorporate
into our judgements about the quality of evidence in the ’Sum-
mary of finding’ tables. We will define outcomes as at low risk of
bias when most information comes from trials at low risk of bias,
unclear risk when most information comes from trials at low or
unclear risk of bias, and high risk when a sufficient proportion of
information comes from trials at high risk of bias.
Measures of treatment effect
When at least two included trials are available for a comparison
and a given outcome, we will try to express dichotomous data as a
risk ratio (RR) or odds ratio (OR) with 95% confidence interval
(CI). For continuous outcomes measured on the same scale (e.g.
weight loss in kg) we will estimate the intervention effect using
the mean difference with 95% CI. For continuous outcomes that
measure the same underlying concept (e.g. health-related quality
of life) but use different measurement scales, we will calculate the
standardised mean difference (SMD). We will express time-to-
event data as a hazard ratio with 95% CI.
Unit of analysis issues
We will take into account the level at which randomisation oc-
curred, such as cross-over trials, cluster-randomised trials andmul-
tiple observations for the same outcome. If more than one com-
parison from the same trial is eligible for inclusion in the same
meta-analysis, we will either combine groups to create a single
pair-wise comparison or appropriately reduce the sample size so
that the same participants do not contributemultiply (splitting the
’shared’ group into two or more groups). While the latter approach
offers some solution to adjusting the precision of the comparison,
it does not account for correlation arising from the same set of
participants being in multiple comparisons (Higgins 2011d).
We will attempt to reanalyse cluster-RCTs that have not appropri-
ately adjusted for potential clustering of participants within clus-
ters in their analyses. The variance of the intervention effects will
be inflated by a design effect. Calculation of a design effect in-
volves estimation of an intra-cluster correlation (ICC). We will
obtain estimates of ICCs through contact with the trial authors,
or impute them using estimates from other included trials that
report ICCs, or using external estimates from empirical research
(e.g. Bell 2013).We plan to examine the impact of clustering using
sensitivity analyses.
Dealing with missing data
If possible, we will obtain missing data from the authors of the
included trials. We will carefully evaluate important numerical
data such as screened, randomly assigned participants as well as
intention-to-treat, and as-treated and per-protocol populations.
We will investigate attrition rates (e.g. dropouts, losses to follow-
up, withdrawals), and we will critically appraise issues concerning
missing data and use of imputation methods (e.g. last observation
carried forward).
In trials where the standard deviation (SD) of the outcome is not
available at follow-up or cannot be recreated, we will standardise
by the average of the pooled baseline SD from those trials that
reported this information.
Where included trials do not report means and SDs for outcomes
andwe do not receive the necessary information from trial authors,
we will impute these values by estimating the mean and variance
from the median, range and the size of the sample (Hozo 2005).
We will investigate the impact of imputation on meta-analyses by
performing sensitivity analyses and we will report per outcome
which trials were included with imputed SDs.
Assessment of heterogeneity
In the event of substantial clinical or methodological heterogene-
ity, we will not report trial results as the pooled effect estimate in
a meta-analysis.
We will identify heterogeneity (inconsistency) by visually inspect-
ing the forest plots and by using a standard Chi² test with a signifi-
cance level of α = 0.1. In view of the low power of this test, we will
also consider the I² statistic, which quantifies inconsistency across
trials to assess the impact of heterogeneity on the meta-analysis
(Higgins 2002; Higgins 2003). An I² statistic value ≥ 75% indi-
cates a considerable level of heterogeneity (Deeks 2011).
When we find heterogeneity, we will attempt to determine the
possible reasons for it by examining individual trial and subgroup
characteristics.
Assessment of reporting biases
If we include 10 or more trials that investigate a particular out-
come, we will use funnel plots to assess small-trial effects. Several
explanations may account for funnel plot asymmetry, including
true heterogeneity of effect with respect to trial size, poor method-
ological design (and hence bias of small trials) and publication bias.
Therefore we will interpret the results carefully (Sterne 2011).
Data synthesis
We plan to undertake (or display) a meta-analysis only if we judge
participants, interventions, comparisons and outcomes to be suf-
ficiently similar to ensure an answer that is clinically meaningful.
Unless good evidence shows homogeneous effects across trials, we
will primarily summarise low risk of bias data using a random-ef-
fects model (Wood 2008). We will interpret random-effects meta-
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analyses with due consideration to the whole distribution of ef-
fects, ideally by presenting a prediction interval (Higgins 2009).
A prediction interval specifies a predicted range for the true treat-
ment effect in an individual trial (Riley 2011). For rare events such
as event rates below 1% we will use Peto’s odds ratio method, pro-
vided that there is no substantial imbalance between intervention
and comparator group sizes and intervention effects are not excep-
tionally large. In addition, we will also perform statistical analyses
according to the statistical guidelines presented in the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011).
Quality of evidence
We will present the overall quality of the evidence for each out-
come specified under ’Types of outcome measures: Summary of
findings’ according to the GRADE approach, which takes into ac-
count issues related to internal validity (risk of bias, inconsistency,
imprecision, publication bias) and also to external validity, such
as directness of results. Two review authors (NN, NN) will inde-
pendently rate the quality of the evidence for each outcome. We
will present a summary of the evidence in a ’Summary of findings’
table. This will provide key information about the best estimate of
the magnitude of the effect, in relative terms and as absolute dif-
ferences, for each relevant comparison of alternative management
strategies, numbers of participants and trials that address each im-
portant outcome and a rating of overall confidence in effect esti-
mates for each outcome. We will create the ’Summary of findings’
table based on the methods described in the Cochrane Handbook
for Systematic Reviews of Interventions (Schünemann 2011), using
Review Manager 5 (RevMan 5) table editor (RevMan 2014). We
will include an appendix titled ’Checklist to aid consistency and
reproducibility of GRADE assessments’ (Meader 2014), to help
with standardisation of the ’Summary of findings’ tables. Alterna-
tively, we will use the GRADEpro Guideline Development Tool
(GDT) software (GRADEproGDT 2014), and will present ev-
idence profile tables as an appendix. We will present results for
the outcomes as described in the Types of outcome measures sec-
tion. If meta-analysis is not possible, we will present the results
narratively in the ’Summary of findings’ table. We will justify all
decisions to downgrade the quality of trials using footnotes and
we will make comments to aid the reader’s understanding of the
Cochrane review where necessary.
Subgroup analysis and investigation of heterogeneity
We expect the following characteristics to introduce clinical het-
erogeneity, and we plan to carry out the following subgroup anal-
yses including investigation of interactions (Altman 2003).
• Partial versus total thyroidectomy.
• Thyroidectomy for cancer versus benign thyroid disease.
• Low vs high experience in thyroid surgery; “low experience
in thyroid surgery” is defined as case-volume of thyroidectomies
less than 25 per year (Adam 2016).
• Residents in general surgery versus surgeons.
• Participants aged less than 75 years versus ≥ 75 years.
• Participants with a body mass index of less than 35 kg/m²
versus body mass index ≥ 35 kg/m².
• Thyroidectomy with tie and clamp versus vascular
dissection, cutting and sealing simultaneously (UltraCision
Harmonic® scalpel) or a bipolar vascular sealing system
(LigaSure®).
Sensitivity analysis
We plan to perform sensitivity analyses to explore the influence of
the following factors (when applicable) on effect sizes by restricting
analysis to the following.
• Published trials.
• The effect of risk of bias, as specified in the Assessment of
risk of bias in included studies section.
• Very long or large trials to establish the extent to which they
dominate the results.
• Using the following filters: diagnostic criteria, imputation,
language of publication, source of funding (industry versus
other), or country.
We will also test the robustness of results by repeating the analyses
using different measures of effect size (RR, OR, etc) and different
statistical models (fixed-effect and random-effects models).
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (OvidSP)
1. Recurrent Laryngeal Nerve Injuries/
2. Vocal Cord Paralysis/
3. Recurrent Laryngeal Nerve/
4. Intraoperative Complications/
5. ((vocal or laryngeal) adj3 (nerve? or pals* or paralys* or injur*)).tw
6. rln.tw.
7. or/1-6
8. exp Monitoring, Intraoperative/
9. Electromyography/
10. monitor*.tw.
11. neuromonitor*.tw.
12. (ionm or rlnm).tw.
13. electromyogra*.tw.
14. or/8-13
15. Thyroidectomy/
16. Thyroid Diseases/su
17. exp Thyroid Neoplasms/su
18. Thyroid Gland/su
19. ((parathyroid or thyroid) adj3 (surg* or dissect* or resect* or cancer or neoplasm? or operat* or malign*)).tw
20. thyroidectom*.tw.
21. or/15-20
22. 7 and 14 and 21
[23-33: Cochrane Handbook 2008 RCT filter - sensitivity maximizing version]
23. randomized controlled trial.pt.
24. controlled clinical trial.pt.
25. randomi?ed.ab.
26. placebo.ab.
27. drug therapy.fs.
28. randomly.ab.
29. trial.ab.
30. groups.ab.
31. or/23-30
32. exp animals/ not humans/
33. 31 not 32
34. 22 and 33
[35: Wong 2006a- systematic reviews filter - SensSpec version]
35. meta analysis.mp,pt. or review.pt. or search*.tw.
36. 22 and 35
37. 34 or 36
Embase (Ovid SP)
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(Continued)
1. recurrent laryngeal nerve injury/
2. recurrent laryngeal nerve palsy/
3. recurrent laryngeal nerve/
4. vocal cord paralysis/
5. peroperative complication/
6. ((vocal or laryngeal) adj3 (nerve? or pals* or paralys* or injur*)).tw
7. rln.tw.
8. or/1-7
9. neurophysiological monitoring/
10. neuromonitoring/
11. electromyography/
12. monitor*.tw.
13. neuromonitor*.tw.
14. (ionm or rlnm).tw.
15. electromyogra*.tw.
16. or/9-15
17. exp thyroid surgery/
18. ((parathyroid or thyroid) adj3 (surg* or dissect* or resect* or cancer or neoplasm? or operat* or malign*)).tw
19. thyroidectom*.tw.
20. or/17-19
21. 8 and 16 and 20
[22: Wong 2006b“sound treatment studies” filter - BS version]
22. random*.tw. or clinical trial*.mp. or exp health care quality/
23. 21 and 22
Cochrane Central Register of Controlled Trials (Cochrane Register of Studies Online)
1. MESH DESCRIPTOR Recurrent Laryngeal Nerve Injuries
2. MESH DESCRIPTOR Vocal Cord Paralysis
3. MESH DESCRIPTOR Recurrent Laryngeal Nerve
4. MESH DESCRIPTOR Intraoperative Complications
5. ((vocal or laryngeal) ADJ3 (nerve? or pals* or paralys* or injur*)):TI,AB,KY
6. rln:TI,AB,KY
7. #1 OR #2 OR #3 OR #4 OR #5 OR #6
8. MESH DESCRIPTOR Monitoring, Intraoperative EXPLODE ALL TREES
9. MESH DESCRIPTOR Electromyography
10. monitor*:TI,AB,KY
11. neuromonitor*:TI,AB,KY
12. (ionm or rlnm):TI,AB,KY
13. electromyogra*:TI,AB,KY
14. #8 OR #9 OR #10 OR #11 OR #12 OR #13
15. MESH DESCRIPTOR Thyroidectomy
16. MESH DESCRIPTOR Thyroid Diseases WITH QUALIFIERS SU
17. MESH DESCRIPTOR Thyroid Neoplasms EXPLODE ALL TREES WITH QUALIFIERS SU
18. MESH DESCRIPTOR Thyroid Gland WITH QUALIFIERS SU
19. ((parathyroid or thyroid) ADJ3 (surg* or dissect* or resect* or cancer or neoplasm? or operat* or malign*)):TI,AB,KY
20. thyroidectom*:TI,AB,KY
21. #15 OR #16 OR #17 OR #18 OR #19 OR #20
22. #7 AND #14 AND #21
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WHO ICTRP Search Portal (standard search)
laryin* AND neuromonitor* OR
vocal AND neuromonitor* OR
rln AND neuromonitor* OR
laryin* AND monitor* OR
vocal AND monitor* OR
rln AND monitor* OR
laryin* AND electromyograph* OR
vocal AND electromyograph* OR
rln AND electromyograph* OR
ionm OR
rlnm
ClinicalTrials.gov (basic search)
(laryngeal OR vocal OR RLN OR complication OR complications) AND (monitor OR neuromonitor OR monitoring OR neu-
romonitoring OR electromyography OR electromyographic OR IONMORRLNM) AND (thyroid OR parathyroid OR thyroidec-
tomy)
Appendix 2. Selection bias decisions
Selection bias decisions for trials reporting unadjusted analyses: comparison of results obtained using method details alone
with results using method details and trial baseline informationa
Reported randomisation and
allocation concealment meth-
ods
Risk of bias judgement using
methods reporting
Information gained from
study characteristics data
Ris of bias using baseline in-
formation and methods re-
porting
Unclear methods Unclear risk Baseline imbalances present for
important prognostic variable
(s)
High risk
Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited or no baseline details Unclear risk
Would generate a truly random
sample, with robust allocation
concealment
Low risk Baseline imbalances present for
important prognostic variable
(s)
Unclear riskc
Groups appear similar at base-
line for all important prognos-
Low risk
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tic variables
Limited baseline details, show-
ing balance in some important
prognostic variablesb
Low risk
No baseline details Unclear risk
Sequence is not truly ran-
domised, or allocation conceal-
ment is inadequate
High risk Baseline imbalances present for
important prognostic variable
(s)
High risk
Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited baseline details, show-
ing balance in some important
prognostic variablesb
Unclear risk
No baseline details High risk
aTaken from Corbett 2014; judgements highlighted in bold indicate situations in which the addition of baseline assessments would
change the judgement about risk of selection bias, compared with using methods reporting alone.
bDetails for the remaining important prognostic variables are not reported.
cImbalance identified that appears likely to be due to chance
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N O T E S
We have based parts of theMethods, as well as Appendix 1 and Appendix 2 of this Cochrane Protocol on a standard template established
by the CMED Group.
The Co-ordinating Editor of the CMED Group will check data extraction, analysis and interpretation of Barczy ski 2009.
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